Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004915
Status:
COMPLETED
Last Update Posted:
2012-06-06
First Post:
2000-03-07
Brief Title:
Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer
Sponsor:
Northwestern University
Organization:
Northwestern University
Study Overview
Official Title:
Phase II Study of Raloxifene in Recurrent Endometrial Cancer
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Estrogen can stimulate the growth of endometrial cancer cells Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen
PURPOSE Phase II trial to study the effectiveness of raloxifene in treating patients who have persistent or recurrent endometrial cancer
PURPOSE Phase II trial to study the effectiveness of raloxifene in treating patients who have persistent or recurrent endometrial cancer
Detailed Description:
OBJECTIVES I Determine response rate and time to disease progression in patients with recurrent endometrial cancer treated with raloxifene II Determine overall survival in these patients treated with this regimen III Determine the toxicity of raloxifene in this patient population
OUTLINE Patients receive oral raloxifene daily Treatment continues indefinitely in the absence of disease progression or unacceptable toxicity Patients are followed every 3 months
PROJECTED ACCRUAL A total of 13-50 patients will be accrued for this study within 25 years
OUTLINE Patients receive oral raloxifene daily Treatment continues indefinitely in the absence of disease progression or unacceptable toxicity Patients are followed every 3 months
PROJECTED ACCRUAL A total of 13-50 patients will be accrued for this study within 25 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1710 | None | None | None |
| NU-98G1 | None | None | None |